SCHEMBL4700752

SCHEMBL4700752

O=C(NC(=O)c1ccccc1Cl)Nc1cc(C(=O)O)ccc1Cl

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PYGL P06737 12/20 0.81
ALDH1A1 P00352 2/20 0.57
KMT2A Q03164 1/20 0.57
MAPT P10636 2/20 0.55
PPARG P37231 1/20 0.55
NR1H4 Q96RI1 1/20 0.55
CYP1A2 P05177 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714080 0.89 MAPT (0.68) PYGLALDH1A1KMT2AMAPTPPARG
SCHEMBL16127883 0.80 PPARG (0.67) PYGLALDH1A1KMT2AMAPTPPARG
SCHEMBL10920514 0.76 PYGL (0.61) PYGLALDH1A1KMT2AMAPTCYP1A2
SCHEMBL14707354 0.76 ALDH1A1 (0.72) PYGLALDH1A1KMT2AMAPTHPGD
SCHEMBL10144149 0.76 ALDH1A1 (0.69) ALDH1A1KMT2AMAPTPPARGNR1H4
SCHEMBL11036755 0.76 RAB9A (0.60) PYGLKMT2AMAPTCYP1A2HPGD
SCHEMBL8840342 0.76 NPC1 (0.60) PYGLALDH1A1KMT2ACYP1A2HPGD
SCHEMBL304416 0.75 POLB (0.69) PYGLALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL31218737 0.75 HTT (0.60) PYGLALDH1A1KMT2AMAPTPPARG
SCHEMBL1459456 0.75 ALDH1A1 (0.71) ALDH1A1KMT2AMAPTPPARGNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404650-B1 CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-02-13 EP disclosed
US-20050143456-A1 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-30 US disclosed
US-6812250-B2 FOR THERAPY TYPE II DIABETES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-02 US disclosed
EP-1404650-A1 CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2004-04-07 EP disclosed
US-20030176497-A1 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-09-18 US disclosed
WO-2002096864-A1 CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143456-A1 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments GLS, MPC2, PC PYGL 102/4885ALDH1A1 647/4885KMT2A 1810/4885
US-20030176497-A1 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments GLS, PC, CPS1 PYGL 123/4885ALDH1A1 384/4885KMT2A 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.